HCPCS code Q5107: Mvasi injection, per 10 mg2026 Medicare rate & RVUs in Missouri
Reports bevacizumab-awwb (Mvasi), an intravenous biosimilar used in oncology treatment, in 10 mg units for the drug administered during a treatment regimen.
CMS doesn’t publish an office rate for Q5107 in Missouri.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What Q5107 covers
Bevacizumab-awwb (Mvasi) is an intravenous biosimilar medicine used in oncology treatment. Oncology practices and hospital infusion departments report Q5107 for the drug administered as part of a treatment regimen. This HCPCS Level II code identifies the medication rather than the infusion administration service; report the applicable administration service separately when performed.
Each unit represents 10 mg, so calculate units by dividing the administered dose in milligrams by 10. CMS assigns physician fee schedule status E, excluding the drug from that schedule. When Medicare covers the item, payment is made under another method; CMS identifies it as a Part B drug generally priced using quarterly Average Sales Price files. Special Medicare coverage instructions apply.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where Q5107 pays more and less in Missouri
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Metropolitan Kansas City, MO | Unavailable | Unavailable |
| Metropolitan St. Louis, MO | Unavailable | Unavailable |
| Rest of Missouri | Unavailable | Unavailable |
How the Q5107 rate is calculated
Each of Q5107’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · Q5107
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for Q5107
Q5107 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · Q5107
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
Q5107 isn’t priced in this setting.
Q5107 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- Q5118Zirabev injectionPer 10 mg
- Use Q5118 for bevacizumab-bvzr (Zirabev); Q5107 is specific to bevacizumab-awwb (Mvasi). Both represent 10 mg units.
- Q5126Alymsys injectionPer 10 mg
- Q5126 identifies bevacizumab-maly (Alymsys). Select between it and Q5107 according to which product was administered.
- J9035BevacizumabPer 10 mg
- J9035 identifies bevacizumab, while Q5107 identifies the bevacizumab-awwb biosimilar. Match the reported code to the product administered.
Q5107 billing questions
What does one unit of Q5107 represent?
One unit represents 10 mg of bevacizumab-awwb. Calculate units from the administered dose in 10 mg increments.
How is Q5107 different from Q5118?
Q5107 identifies bevacizumab-awwb (Mvasi), while Q5118 identifies bevacizumab-bvzr (Zirabev). Select the code for the specific product administered.
Is the infusion administration service included in Q5107?
Q5107 identifies the drug rather than the administration service. Report the applicable administration service separately when performed.
Does Medicare pay Q5107 under the physician fee schedule?
CMS assigns status E, excluding the drug from the physician fee schedule. When Medicare covers it, payment is handled through another method; Part B drug pricing generally uses quarterly ASP files.
What should the medical record support?
Document the product administered and the dose so the reported 10 mg units can be substantiated.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put Q5107 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist